Primary biliary cholangitis (PBC) is a disease characterized by autoimmune destruction of small bile ducts, thereby preventing bile mobilization and increasing hepatic bile content. These symptoms lead to progressive liver damage and drive morbidity and mortality in PBC patients. The goals of treatment for PBC are to halt or slow progression of liver disease, reduce the need for liver transplantation, lower the risk of mortality, and alleviate symptoms (e.g., fatigue, itch). Ursodeoxycholic acid (UDCA) is the cornerstone of PBC treatment, and Intercept’s Ocaliva is an option for patients who respond inadequately to UDCA. Although these drugs improve outcomes, they do not address the underlying autoimmune defect or meaningfully improve symptoms associated with PBC. As a result, most PBC patients are also concurrently prescribed symptomatic treatments.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed primary biliary cholangitis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed primary biliary cholangitis patients?
- What proportion of primary biliary cholangitis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of primary biliary cholangitis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with primary biliary cholangitis?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.